Clinicopathological Features of KRAS-Mutated Colon Cancer: An Analytical Cross-Sectional Study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Colon cancer patients with Kirsten rat sarcoma oncogene (KRAS) mutations often present with sigmoid colon tumors. Co-occurring BRAF mutations in KRAS-positive cases suggest molecular interactions impacting disease progression.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Colon cancer is a significant global health concern.
- Kirsten rat sarcoma oncogene (KRAS) mutations are prevalent in 35-45% of colorectal cancer (CRC) patients.
- KRAS mutations are crucial biomarkers for CRC detection, prognosis, and treatment.
Purpose Of The Study
- To identify clinicopathological characteristics of colon cancer patients with KRAS mutations.
- To explore the relationship between KRAS mutations and other genetic alterations, such as BRAF mutations.
- To understand the clinical implications of KRAS mutations in colon cancer.
Main Methods
- An analytical cross-sectional study was conducted on CRC patients.
- Data collected included patient demographics, tumor location, KRAS and BRAF mutation status, and TNM staging.
- Statistical analysis was performed to identify correlations between variables.
Main Results
- The study included 51 patients with a mean age of 61.4 years.
- KRAS mutations were found in 35% of patients, and BRAF mutations in 32%.
- A significant association was observed between KRAS and BRAF mutations (P=0.02), with 61.1% of KRAS-positive patients also having BRAF mutations.
Conclusions
- KRAS-positive colon cancer patients frequently exhibit tumors in the sigmoid colon.
- The co-occurrence of KRAS and BRAF mutations may indicate molecular interactions influencing colon cancer progression.
- Further research is warranted to elucidate the clinical significance of these genomic patterns.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...